Brakke Consulting will help with the sale and licensing of technology used in a Texas company’s newly patented snakebite vaccine for companion animals and horses.
Tejas Discovery and Research’s technology “provides for encapsulation and a steady, slow-release presentation of detoxified rattlesnake venom to the immune system, which results is a high-titer, long-lasting antibody response without any local or systemic adverse events,” Brakke reported.
“Snake envenomation is an important presenting problem at veterinary clinics,” said Tejas co-founder William Campaigne, DVM.
In other news, Brakke:
- Appointed Jim Kroman to its team of consultants. Kroman retired in 2017 as executive director of business development, licensing and project management at Boehringer Ingelheim Vetmedica.
- Launched the tracking study “COVID-19: Impact on Pet Care.” The study will be conducted in three waves beginning in May, Brakke reported, and is available for purchase by emailing senior consultant John Volk at john@volkonline.com.
Brakke, which is headquartered in Greensboro, North Carolina, serves the animal health, animal nutrition and veterinary industries.
Did you know a subscription to Today’s Veterinary Business is free to qualified veterinary professionals? All you have to do is sign up here (and renew each year). You also can sign up to receive the Today’s Veterinary Business weekly e-newsletter.